Cargando…
Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morpholog...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Österreichische Apotheker-Verlagsgesellschaft
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002797/ https://www.ncbi.nlm.nih.gov/pubmed/21179351 http://dx.doi.org/10.3797/scipharm.0908-12 |
_version_ | 1782193785433751552 |
---|---|
author | Nakarani, Mahendra Patel, Priyal Patel, Jayvadan Patel, Pankaj Murthy, Rayasa S. R. Vaghani, Subhash S. |
author_facet | Nakarani, Mahendra Patel, Priyal Patel, Jayvadan Patel, Pankaj Murthy, Rayasa S. R. Vaghani, Subhash S. |
author_sort | Nakarani, Mahendra |
collection | PubMed |
description | Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one. |
format | Text |
id | pubmed-3002797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Österreichische Apotheker-Verlagsgesellschaft |
record_format | MEDLINE/PubMed |
spelling | pubmed-30027972010-12-22 Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation Nakarani, Mahendra Patel, Priyal Patel, Jayvadan Patel, Pankaj Murthy, Rayasa S. R. Vaghani, Subhash S. Sci Pharm Original Papers Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one. Österreichische Apotheker-Verlagsgesellschaft 2010 2010-04-26 /pmc/articles/PMC3002797/ /pubmed/21179351 http://dx.doi.org/10.3797/scipharm.0908-12 Text en © Nakarani et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Papers Nakarani, Mahendra Patel, Priyal Patel, Jayvadan Patel, Pankaj Murthy, Rayasa S. R. Vaghani, Subhash S. Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation |
title | Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation |
title_full | Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation |
title_fullStr | Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation |
title_full_unstemmed | Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation |
title_short | Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation |
title_sort | cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002797/ https://www.ncbi.nlm.nih.gov/pubmed/21179351 http://dx.doi.org/10.3797/scipharm.0908-12 |
work_keys_str_mv | AT nakaranimahendra cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation AT patelpriyal cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation AT pateljayvadan cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation AT patelpankaj cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation AT murthyrayasasr cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation AT vaghanisubhashs cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation |